SARS Spike Protein (S1 Domain) BS-6100 (1 mg)

£728.00

1 mg

SKU: BS-6100

Recombinant SARS CoV Spike protein S1 domain fused to the Fc region of human Ig essentially as described by Li W et al., Nature 426:450-4 (2003). The polypeptide contains amino acids 19-713 of the spike protein.

Activity: Purified SCoV S1-Fc is active in binding the Vero E6 cell surface and recombinant ACE2.
Presentation: Freeze-dried in PBS without preservative.
Composition: Recombinant SARS-CoV Spike Protein S1 domain fused to the Fc region of human Ig essentially as described Li W et al., Nature 426:450-4 (2003). The polypeptide contains amino acids 19-713 of the Spike Protein.
Preparation: The S1-fusion protein expressed using recombinant baculoviruses and purified from the infected cell supernatant by protein A affinity chromatography.
Purity: >90 %.
Endotoxin: Endotoxin level is < 0.1 ng/μg of protein (<1 EU/μg)
Expressed Host: Baculovirus-Insect Cells. The S1-Fc fusion protein expressed using recombinant baculoviruses and purified from the infected cell supernatant.
Species: 2019-nCoV
Formulation: Freeze-dried in PBS without preservative.
Storage: Desiccated at +2 to +8°C. Reconstituted product should be stored in aliquots at –20°C.
Regulatory/Restrictions: For Research Use Only.

The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV-2 spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S RBD protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV-2 (2019-nCoV) as in recent COVID-19 outbreak.